Pembrolizumab Liquid
NDC Package 83012-010-99

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Pembrolizumab liquids is pembrolizumab is used to treat cancer. This formulation utilizes a liquid delivery system. Marketed by Boehringer Ingelheim Fremont, Inc., this product is identified by NDC 83012-010.

Identification & Billing

NDC Package Code
83012-010-99
Package Description
25 mg in 1 BAG
Product Code
83012-010
11-Digit Billing Format
83012001099

Clinical Specifications

Proprietary Name
Pembrolizumab
Non-Proprietary Name
Pembrolizumab
Substance Name
Pembrolizumab
Dosage Form
Liquid - A dosage form consisting of a pure chemical in its liquid1 state. This dosage form term should not be applied to solutions.
Active Ingredient(s)
PEMBROLIZUMAB 25 mg/25mg
Usage Information
Pembrolizumab is used to treat cancer. It works by changing the action of your own immune system, directing it to attack cancer cells. Pembrolizumab belongs to a class of drugs known as monoclonal antibodies.

Regulatory & Marketing

Labeler Name
Boehringer Ingelheim Fremont, Inc.
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
04-26-2021
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 83012-010-99 identifies a specific commercial package of 25 mg in 1 bag of Pembrolizumab (UNFINISHED drug), a bulk ingredient labeled by Boehringer Ingelheim Fremont, Inc.. This liquid is formulated for use and contains pembrolizumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Boehringer Ingelheim Fremont, Inc. on April 26, 2021. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Pembrolizumab is used to treat cancer. It works by changing the action of your own immune system, directing it to attack cancer cells. Pembrolizumab belongs to a class of drugs known as monoclonal antibodies.

How is this Boehringer Ingelheim Fremont, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 83012001099. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
83012-010-99
11-Digit CMS (5-4-2)
83012-0010-99

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.